Stockscreener 앱 받기
3.545
3.35%
0.115
시간 외 거래:
3.55
0.005
+0.14%
Polypid Ltd 주식(PYPD)의 최신 뉴스
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
PolyPid Announces $8.25 Million Share Sale Plan - TipRanks
PYPDPolyPid Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - StockTitan
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire
Will PolyPid Wield The SHIELD? - RTTNews
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com
PolyPid Announces Publication in International Journal of - GlobeNewswire
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan
PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa
PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India
PolyPid completes enrollment for phase 3 trial - Investing.com
PolyPid Nears Completion of Key Phase 3 Trial - TipRanks
PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan
PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire
Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World
HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: PolyPid reports a net loss of $6.3 million in the second-quarter of 2024 - Investing.com
PolyPid Reports Growth in Mid-Year Assets - TipRanks
PolyPid Advances SHIELD II Trial with Solid Financing - TipRanks
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Analyzing Silk Road Medical (NASDAQ:SILK) & PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (PYPD) Scheduled to Post Earnings on Wednesday - Defense World
PolyPid secures $14 million in private placement - Investing.com
PolyPid secures $14 million in private placement By Investing.com - Investing.com UK
PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial - TipRanks
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds - StockTitan
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - GlobeNewswire
PolyPid stock hits 52-week low at $3.35 amid market challenges - Investing.com
1.89%
2.08%
자본화:
|
볼륨(24시간):